Loading…
CTCs in early breast cancer: A path worth taking
Highlights • CTC value in early breast cancer (EBC) is still not fully accepted. • CTCs are proving a great potential in EBC. • CTCs will contribute to a better understanding and clinical management of EBC.
Saved in:
| Published in: | Cancer letters 2016-07, Vol.376 (2), p.205-210 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c445t-6f02c348548ce91e6fb80b745fb367075c78644a867bf03a916e4191ffb2c6853 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c445t-6f02c348548ce91e6fb80b745fb367075c78644a867bf03a916e4191ffb2c6853 |
| container_end_page | 210 |
| container_issue | 2 |
| container_start_page | 205 |
| container_title | Cancer letters |
| container_volume | 376 |
| creator | Maltoni, Roberta Gallerani, Giulia Fici, Pietro Rocca, Andrea Fabbri, Francesco |
| description | Highlights • CTC value in early breast cancer (EBC) is still not fully accepted. • CTCs are proving a great potential in EBC. • CTCs will contribute to a better understanding and clinical management of EBC. |
| doi_str_mv | 10.1016/j.canlet.2016.03.051 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1787762811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383516302129</els_id><sourcerecordid>4051070831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-6f02c348548ce91e6fb80b745fb367075c78644a867bf03a916e4191ffb2c6853</originalsourceid><addsrcrecordid>eNqFkU1r3DAQhkVJaTZp_0Eohlx6sTv6lnMILEvzAYEekpyFrB032njtreRN2H9fuZu0kEsuGgTPvCM9Q8gJhYoCVd9XlXd9h2PF8q0CXoGkH8iMGs1KXRs4IDPgIEpuuDwkRymtAEAKLT-RQ6ZBAQM5I7C4W6Qi9AW62O2KJqJLY5GTPcazYl5s3PhQPA8xn6N7DP2vz-Rj67qEX17qMbm_-HG3uCpvfl5eL-Y3pRdCjqVqgXkujBTGY01RtY2BRgvZNlxp0NJro4RwRummBe5qqlDQmrZtw7wykh-Tb_vcTRx-bzGNdh2Sx65zPQ7bZKk2WitmKM3o6Rt0NWxjn1_3lzKGAkyU2FM-DilFbO0mhrWLO0vBTkbtyu6N2smoBW6z0dz29SV826xx-a_pVWEGzvcAZhtPAaNNPmD2twwR_WiXQ3hvwtsA34U-eNc94g7T_7_YxCzY22mr01Kp4sAoq_kfedCZqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1787881001</pqid></control><display><type>article</type><title>CTCs in early breast cancer: A path worth taking</title><source>Elsevier</source><creator>Maltoni, Roberta ; Gallerani, Giulia ; Fici, Pietro ; Rocca, Andrea ; Fabbri, Francesco</creator><creatorcontrib>Maltoni, Roberta ; Gallerani, Giulia ; Fici, Pietro ; Rocca, Andrea ; Fabbri, Francesco</creatorcontrib><description>Highlights • CTC value in early breast cancer (EBC) is still not fully accepted. • CTCs are proving a great potential in EBC. • CTCs will contribute to a better understanding and clinical management of EBC.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2016.03.051</identifier><identifier>PMID: 27060205</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; Biomarkers, Tumor - blood ; Biopsy ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer therapies ; Circulating tumor cells ; Clinical evidence ; Conflicts of interest ; Drug resistance ; Early breast cancer ; Early Detection of Cancer - methods ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Liquid biopsy ; Lymphatic system ; Medical prognosis ; Metastasis ; Mortality ; Neoplasm Metastasis ; Neoplasm, Residual ; Neoplastic Cells, Circulating - drug effects ; Neoplastic Cells, Circulating - metabolism ; Neoplastic Cells, Circulating - pathology ; Predictive Value of Tests ; Surgery ; Time Factors ; Treatment Outcome</subject><ispartof>Cancer letters, 2016-07, Vol.376 (2), p.205-210</ispartof><rights>2016 Elsevier Ireland Ltd</rights><rights>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jul 1, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-6f02c348548ce91e6fb80b745fb367075c78644a867bf03a916e4191ffb2c6853</citedby><cites>FETCH-LOGICAL-c445t-6f02c348548ce91e6fb80b745fb367075c78644a867bf03a916e4191ffb2c6853</cites><orcidid>0000-0003-0663-2829 ; 0000-0003-0121-9621</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27060205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maltoni, Roberta</creatorcontrib><creatorcontrib>Gallerani, Giulia</creatorcontrib><creatorcontrib>Fici, Pietro</creatorcontrib><creatorcontrib>Rocca, Andrea</creatorcontrib><creatorcontrib>Fabbri, Francesco</creatorcontrib><title>CTCs in early breast cancer: A path worth taking</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • CTC value in early breast cancer (EBC) is still not fully accepted. • CTCs are proving a great potential in EBC. • CTCs will contribute to a better understanding and clinical management of EBC.</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer therapies</subject><subject>Circulating tumor cells</subject><subject>Clinical evidence</subject><subject>Conflicts of interest</subject><subject>Drug resistance</subject><subject>Early breast cancer</subject><subject>Early Detection of Cancer - methods</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Liquid biopsy</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm, Residual</subject><subject>Neoplastic Cells, Circulating - drug effects</subject><subject>Neoplastic Cells, Circulating - metabolism</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Predictive Value of Tests</subject><subject>Surgery</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkU1r3DAQhkVJaTZp_0Eohlx6sTv6lnMILEvzAYEekpyFrB032njtreRN2H9fuZu0kEsuGgTPvCM9Q8gJhYoCVd9XlXd9h2PF8q0CXoGkH8iMGs1KXRs4IDPgIEpuuDwkRymtAEAKLT-RQ6ZBAQM5I7C4W6Qi9AW62O2KJqJLY5GTPcazYl5s3PhQPA8xn6N7DP2vz-Rj67qEX17qMbm_-HG3uCpvfl5eL-Y3pRdCjqVqgXkujBTGY01RtY2BRgvZNlxp0NJro4RwRummBe5qqlDQmrZtw7wykh-Tb_vcTRx-bzGNdh2Sx65zPQ7bZKk2WitmKM3o6Rt0NWxjn1_3lzKGAkyU2FM-DilFbO0mhrWLO0vBTkbtyu6N2smoBW6z0dz29SV826xx-a_pVWEGzvcAZhtPAaNNPmD2twwR_WiXQ3hvwtsA34U-eNc94g7T_7_YxCzY22mr01Kp4sAoq_kfedCZqw</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Maltoni, Roberta</creator><creator>Gallerani, Giulia</creator><creator>Fici, Pietro</creator><creator>Rocca, Andrea</creator><creator>Fabbri, Francesco</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0663-2829</orcidid><orcidid>https://orcid.org/0000-0003-0121-9621</orcidid></search><sort><creationdate>20160701</creationdate><title>CTCs in early breast cancer: A path worth taking</title><author>Maltoni, Roberta ; Gallerani, Giulia ; Fici, Pietro ; Rocca, Andrea ; Fabbri, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-6f02c348548ce91e6fb80b745fb367075c78644a867bf03a916e4191ffb2c6853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer therapies</topic><topic>Circulating tumor cells</topic><topic>Clinical evidence</topic><topic>Conflicts of interest</topic><topic>Drug resistance</topic><topic>Early breast cancer</topic><topic>Early Detection of Cancer - methods</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Liquid biopsy</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm, Residual</topic><topic>Neoplastic Cells, Circulating - drug effects</topic><topic>Neoplastic Cells, Circulating - metabolism</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Predictive Value of Tests</topic><topic>Surgery</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maltoni, Roberta</creatorcontrib><creatorcontrib>Gallerani, Giulia</creatorcontrib><creatorcontrib>Fici, Pietro</creatorcontrib><creatorcontrib>Rocca, Andrea</creatorcontrib><creatorcontrib>Fabbri, Francesco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maltoni, Roberta</au><au>Gallerani, Giulia</au><au>Fici, Pietro</au><au>Rocca, Andrea</au><au>Fabbri, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CTCs in early breast cancer: A path worth taking</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>376</volume><issue>2</issue><spage>205</spage><epage>210</epage><pages>205-210</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights • CTC value in early breast cancer (EBC) is still not fully accepted. • CTCs are proving a great potential in EBC. • CTCs will contribute to a better understanding and clinical management of EBC.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>27060205</pmid><doi>10.1016/j.canlet.2016.03.051</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0663-2829</orcidid><orcidid>https://orcid.org/0000-0003-0121-9621</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2016-07, Vol.376 (2), p.205-210 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1787762811 |
| source | Elsevier |
| subjects | Animals Antineoplastic Agents - therapeutic use Biomarkers, Tumor - blood Biopsy Breast cancer Breast Neoplasms - blood Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer therapies Circulating tumor cells Clinical evidence Conflicts of interest Drug resistance Early breast cancer Early Detection of Cancer - methods Female Hematology, Oncology and Palliative Medicine Humans Liquid biopsy Lymphatic system Medical prognosis Metastasis Mortality Neoplasm Metastasis Neoplasm, Residual Neoplastic Cells, Circulating - drug effects Neoplastic Cells, Circulating - metabolism Neoplastic Cells, Circulating - pathology Predictive Value of Tests Surgery Time Factors Treatment Outcome |
| title | CTCs in early breast cancer: A path worth taking |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A47%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CTCs%20in%20early%20breast%20cancer:%20A%20path%20worth%20taking&rft.jtitle=Cancer%20letters&rft.au=Maltoni,%20Roberta&rft.date=2016-07-01&rft.volume=376&rft.issue=2&rft.spage=205&rft.epage=210&rft.pages=205-210&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2016.03.051&rft_dat=%3Cproquest_cross%3E4051070831%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c445t-6f02c348548ce91e6fb80b745fb367075c78644a867bf03a916e4191ffb2c6853%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1787881001&rft_id=info:pmid/27060205&rfr_iscdi=true |